David Feltquate joins iTeos as Chief Medical Officer
iTeos Therapeutics shared a post on LinkedIn
“Please join us in welcoming Dr. David Feltquate as Chief Medical Officer at iTeos! Dr. Feltquate joins the company at a pivotal moment in our journey to become a leading oncology company.
Recognized for his nearly 20 years in immuno-oncology clinical development, translational medicine, and diagnostic assay advancement experience, Dr. Feltquate was formerly the Chief Medical Officer at Palleon Pharmaceuticals.
Earlier in his career, he was Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis, and Head of Oncology Early Clinical Development and Development Leader of Ipilimumab / Nivolumab Life Cycle Management at Bristol Myers Squibb.”
Source: iTeos Therapeutics/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023